From a cup of coffee to a high-tech laboratory for hematology testing





Prof. Jonathan Douxfils
University of Namur
QUALIblood s.a.

12 MARS MAART 2019

MARCHE-EN-FAMENNE

Genesis of QUALIblood

2010

Creation of the NTHC

2011-2015

PhD thesis in the field of hematological biomarkers innovations and validations 2013-2017

Validations of diagnostic kits in collaboration with IVD manufacturers 2016

Collaboration with Biotech companies Entrepreneurs

hip courses Market study

ADRE - WBC -BEP 2017

DGO 6 – Bourse préactivité Deposit mark Contact with

investors



12 MARS
MAART
2019

MARCHE-EN-FAMENNE

Genesis of QUALIblood

Start-up from the **University of Namur**

More than 10 years of research in **hematology** with a focus on **hemostasis** and **hemocompatibility** - more than 100 publications in the field with innovative biomarkers development and discovery

Gathering of expertise from laboratory, clinical and regulatory scientists



Potential market needs



Antithrombotics 19 billions \$ CAGR 7.6%

193 products in development

Female hormonal therapies 10 billions \$

Antineoplasic agents (TKI) 40 millions \$

12 MARS MAART 2019

MARCHE-EN-FAMENNE

Commercial strategy

Scientific contacts:

Publications, studies, collaborations



Representation:

Presence at international congress, presentation of clinical studies



Define the offer

We often hear...

"The haematological environment is so complex and a plenty of tests are so constantly renewed that a continuous expertise in this field is hard to reach"

"I risk my time and money in inefficient or outdated blood testing. Could a specific laboratory help me in the choice of the most appropriate biomarkers to ensure transferability to real-world applications?"





Define the offer

Because every result matters, QUALIblood is offering to **pharmaceutical** and **IVD companies** a tailor-made accompaniment in blood analyses.

Define the offer

FACILITIES FOR PHARMACEUTICAL COMPANIES

DEFINITION OF ANALYTICAL PROTOCOLS

- ACCOMPANIMENT IN THE REDACTION OF THE PROTOCOL
- ADVICE AND LITERATURE REVIEW FOR DETERMINATION OF MOST APPROPRIATE BIOMARKERS

PRE-CLINICAL INVESTIGATIONS – GRP AND/OR GLP AND ISO 13485* & 17025*

- IN VITRO INVESTIGATION ON PLASMA, SERUM, WHOLE BLOOD OR CELL LINES
- TAILOR-MADE SOLUTIONS AND TESTING VALIDATED ACCORDING TO REGULATORY REQUIREMENTS
- BLOOD TESTING OF SAMPLES FROM ANIMAL STUDIES

CLINICAL INVESTIGATIONS - GLP AND ISO 13485* & 17025*

■ BLOOD TESTING OF SAMPLES FROM HUMAN STUDIES — PHASE I TO III

BATCH RELEASE - GLP AND ISO 13485* & 17025*

 EVALUATION OF THE QUALITY OF PLASMA-DERIVED MEDICINAL PRODUCT ACCORDING TO REGULATORY REQUIREMENTS

FACILITIES FOR IVD COMPANIES

DEFINITION OF ANALYTICAL PROTOCOL

ACCOMPANIMENT IN THE REDACTION OF THE PROTOCOL

PROOF-OF-CONCEPT - GRP AND/OR GLP AND ISO 13485*

- IN VITRO INVESTIGATION ON PLASMA, SERUM FROM OUR PROSPECTIVE BIOBANK
- IN-VITRO INVESTIGATION ON PLASMA, SERUM OR WHOLE BLOOD FROM HEALTHY SUBJECTS
- METHOD COMPARISON ON SEVERAL ANALYTICAL PLATFORMS WHEN AVAILABLE
- EARLY ADVICES FOR METHOD IMPROVEMENT

ANALYTICAL PERFORMANCE - GLP AND ISO 13485*

- DEFINITION OF ANALYTICAL PERFORMANCES ACCORDING TO REGULATORY TEMPLATES VALIDATION PROCESS
- DEFINITION OF NORMAL RANGE FROM OUR AVAILABLE BIOBANK FROM HEALTHY SUBJECTS

REAL-LIFE EVALUATIONS - GLP AND ISO 13485*

- STUDY PERFORMED IN COLLABORATION WITH OUR UNIVERSITY PARTNERS
- SUPERVISION OF MULTI-SITE STUDIES

* ISO certifications are pending

12 MARS MAART 2019



Partners and first customers

Partners and invests











Customers










12 MARS MAART 2019



2016-2017


Pivotal years





12 MARS MAART 2019





Copyright QUALIblood SA. All rights reserved. May not be reproduced without permission. All hard copies should be checked against the current electronic version within Document Control System prior to use and destroyed promptly thereafter. All hard copies are considered uncontrolled.

12 MARS MAART 2019

MARCHE-EN-FAMENNE

Growth plan

Management of serious contracts of phase-III studies

New laboratory
(✓ Infrastructure)

GLP and ISO implementation

GLP and ISO certification

Refinancing

Batch release prospection

University exit

Laboratory installation for GLP certification

2017 2018 2019 2020 2021

12 MARS MAART 2019



Take home message and advice


As a medical scientist, there is a real need to follow specific entrepreneurship courses

Fundamental or medical sciences are not business science, so don't see businessman as profiteers of your ideas but rather as a catalyst

Continue to elaborate your scientific network by publishing, attending congress and so on, this is the core business of your society

Hire different profiles and people for which you would like to work for! As a small company each collaborators is of utmost importance!

Keep your motivation for innovation and enjoy the adventure!



"The human mind is like a parachute. It works best when it is open"